Rubius Therapeutics (RUBY) Peer Comparison

$0.06

$0.04 (171.43%)

As on 29-Dec-2023 15:49EDT

Market cap

$5 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.3

Div. Yield

0 %

Edit

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	5	16,765	13,492	11,994	11,957
Revenue ($ Mln)	--	2,782	2,436	670	1,664
Net Profit ($ Mln)	-230.86	491.50	860.62	-319.95	413.60
Net Margin (%)	-295,883.54	17.67	35.33	-47.79	24.86
RoE (%)	-238.11	110.09	42.98	-71.14	430.03
Price to Earnings	--	35.25	17.40	--	30.89
Price-To-Book	0.34	39.29	7.42	26.87	84.52

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	0.00	1,460.00	1,611.06	243.23	660.12
Cost of Revenue	--	1,027.56	57.91	10.42	139.30
Gross Profit	--	432.44	1,553.15	243.23	520.81
Operating Expenses	127.25	153.74	1,351.67	421.74	253.28
Operating Profit (EBIT)	-178.45	278.70	201.48	-178.51	267.53
Other Income	--	7.07	-0.20	0.77	-1.67
Profit before Tax	-179.67	282.86	234.35	-172.71	248.92
Provision for Tax	51.20	37.49	52.07	3.79	46.79
Profit after Tax (Net Income)	-230.86	245.37	182.28	-176.49	202.13
Minority Interest	--	--	--	19.82	--
Consolidated Profit	-179.67	245.37	182.28	-176.06	202.13

Liabilities ($ Mln)

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	15.13	386.39	2,488.43	398.52	169.80
Minority Interest	--	--	--	19.82	--
Non-Current Liabilities	1.10	162.64	258.70	134.75	1,540.92
Current Liabilities	7.94	803.47	324.36	138.85	130.79
Total Liabilities	23.07	1,352.50	3,071.49	691.94	1,841.51

Assets ($ Mln)

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	2.88	1,018.53	1,452.73	286.64	1,102.50
Current Assets	20.20	333.96	1,618.76	405.30	739.01
Total Assets	23.07	1,352.50	3,071.49	691.94	1,841.51
Total Debt*	1.10	188.87	190.17	81.58	1,506.10
Net Current Assets	12.26	-469.51	1,294.40	302.30	608.22

Cashflow ($ Mln)

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-150.14	388.05	362.61	-136.13	240.11
Cash Flow from Investing Activities	12.94	-38.74	-524.41	-5.42	-487.01
Cash from Financing Activities	-75.47	-775.78	0.59	65.19	362.37
Net Cash Inflow / Outflow	--	-426.47	-161.21	-76.36	115.48

Ratios

Profitability Ratios

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-149.68	29.58	7.38	-38.60	14.70
ROE (%)	-238.11	36.64	7.76	-43.72	110.23
ROA (%)	-135.37	16.29	6.41	-25.18	13.72
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	--	16.73	11.32	-72.33	30.70
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	--	0.28	0.12	0.76	0.49
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-22.26	34.93	-21.11	-25.31	-49.81
EPS Growth (%)	-0.22	0.57	-0.21	-0.24	-0.48
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	-0.07	28.07	28.45	-19.80	39.02
Price / Book Value	1.04	17.82	2.08	8.77	46.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.02	22.87	18.29	-19.04	28.62
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.07	0.49	0.08	0.20	8.87
Short term debt to equity ratio	0.07	0.13	0.01	0.01	0.08
Current Ratio	2.54	0.42	4.99	2.92	5.65
Quick Ratio	--	--	4.89	3.07	4.88
Interest Coverage	-46.19	98.37	3.75	-35.47	15.69

Operating Efficiency Ratios

	Rubius Therapeutics (RUBY)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	--	17.36	13.33	0.58	35.00
Asset Turnover	0.00	0.97	0.57	0.35	0.45
Receivable days	--	55.02	56.39	8.76	89.10
Inventory Days	--	--	191.72	-302.34	201.93
Payable days	--	10.44	179.52	215.99	25.22
Cash Conversion Cycle	--	--	68.58	-509.57	265.81

Annual
Quarterly